NCI (US National Cancer Institute) seeks partner to develop oesophageal cell sampler:
This article was originally published in Clinica
The US National Cancer Institute (NCI) is looking for a partner to help it develop and commercialise a better method of obtaining cell samples from the oesophagus for cancer screening. Cytologic samples are currently gathered using an inflatable balloon or an encapsulated sponge. The technique is poor at picking up early signs of cancer and needs to be improved, says the NCI. The cooperative research and development agreement is expected to last four years.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.